We are beginning clinical testing of the BacterOMIC system at a third third third-party laboratory.
The addition of a third independent center will allow precise clinical evaluation of the BacterOMIC system. The next step will be to obtain the CE-IVD mark, which will allow us to start marketing the device in Europe.
BacterOMIC is the first system in the world to provide the ability to quantitatively assess the drug susceptibility of a wide pool of antibiotics in a single test.
A unique microfluidic solution allowing cultures in 640 chambers provides the ability to test mixtures of antibiotics to quantify synergies of action. This provides the opportunity to select treatment for the most severe cases of infections with multidrug-resistant bacteria.